CLINICAL DEVELOPMENT OF GAMITRINIB, A NOVEL MITOCHONDRIAL-TARGETED SMALL MOLECULE HSP90 INHIBITOR

$1,873,798FY2013Department of DefenseDOD

The Wistar Institute Of Anatomy And Biology

Investigators